Related Experiment Videos
Epidermal growth factor receptor and bladder cancer
1University Division of Urology, Leicester General Hospital, Gwendolen Road, Leicester, UK.
Postgraduate Medical Journal
|November 5, 2002
Summary
Muscle-invasive bladder cancer has a low survival rate. Targeting epidermal growth factor receptor (EGFR) with anti-EGFR therapy may improve outcomes when combined with standard treatments.
Area of Science:
- Oncology
- Cancer Research
Background:
- Muscle-invasive bladder cancer presents significant mortality and morbidity.
- Current treatments like radical cystectomy and radiotherapy yield a low 5-year survival rate of 40%.
- Epidermal growth factor receptor (EGFR) overexpression is a known poor prognostic factor in bladder cancer.
Purpose of the Study:
- To explore the potential of anti-EGFR therapy as an adjunct treatment for muscle-invasive bladder cancer.
- To investigate if targeting EGFR can improve survival rates in patients with this condition.
Main Methods:
- Review of clinical and molecular risk factors in muscle-invasive bladder cancer.
- Analysis of EGFR expression in bladder tumors.
- Evaluation of potential EGFR inhibition strategies.
Main Results:
- EGFR is frequently overexpressed in epithelial tumors, including bladder cancer.
- Several methods exist for inhibiting EGFR activity.
Conclusions:
- Combination therapy involving anti-EGFR agents and conventional treatments may offer a novel approach to improve prognosis.
- Further research into anti-EGFR therapies is warranted for muscle-invasive bladder cancer management.